Compare organizations

The Association of Innovative Pharmaceutical Industry (AIFP) shares the EFPIA’s view expressed in its input into this Inception Impact Assessment. Further to this, we would like to stress some of our main concerns and observations. The European citizens expect to have equal access to safe, state-of-the-art and affordable innovative and established therapies.

The American Chamber of Commerce to the EU (AmCham EU) is committed to the development of a regulatory environment which furthers the capabilities of European healthcare, improving accessibility and ensuring a crisis-resistant medicines regulatory system.

Introduction To be truly future proof and innovation friendly, the EU's proposed pharmaceutical package must address the blocs declining attractiveness for investment. We therefore urge EU co-legislators to secure globally competitive incentives for research and development (R&D) and avoid additional unnecessary administrative burdens on companies.

Introduction To be truly future proof and innovation friendly, the EU's proposed pharmaceutical package must address the blocs declining attractiveness for investment. We therefore urge EU co-legislators to secure globally competitive incentives for research and development (R&D) and avoid additional unnecessary administrative burdens on companies.

The Association of Innovative Pharmaceutical Industry (AIFP) shares the EFPIA’s view expressed in its input into this Inception Impact Assessment. Further to this, we would like to stress some of our main concerns and observations.

The American Chamber of Commerce to the European Union (AmCham EU) shares the European Commission’s view that EU-level action is required to address the fragmented environment of European health data, the lack of data available for (re-)use in scientific research and the need for increased uniformity in Member States’ applications of data regulations.

AmCham EU speaks for American companies committed to Europe on trade, investment and competitiveness issues. It aims to ensure a growth-orientated business and investment climate in Europe. AmCham EU facilitates the resolution of transatlantic issues that impact business and plays a role in creating better understanding of EU and US positions on business matters.

EuropaBio welcomes the European Commission’s bold ambition to make Europe the most competitive data economy globally. The power of data in the healthcare sphere is evident and realising the potential of healthcare data is a crucial step to ensure the EU is a leader in the development of next generational medicines.

The Association of Innovative Pharmaceutical Industry (AIFP) shares the EFPIA´s view expressed in its input into this Inception Impact Assessment. Further to this we would like to stress some of our main concerns and observations.

Representing American companies operating in the EU, AmCham EU is well aware of the differences and respective strengths of innovation ecosystems on both sides of the Atlantic. The options laid out in the inception impact assessment (IIA) risk undermining an EU framework that has proven largely successful, rather than preserving the EU’s strengths and incorporating learnings from other regions.